26406 Federal Register / Vol. 72, No. 89 / Wednesday, May 9, 2007 / Notices 

Collaborative Research Opportunity: 

The NIDCD Otolaryngology Branch is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize this 

technology as well as collaborate on 

further pre-clinical and clinical studies 

with the TMC2 gene mutations. Please 

contact Ms. Marianne Lynch at 301–

402–5579 or via e-mail at 

lynchm@nhlbi.nih.gov for more 

information. 

Dated: April 30, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8894 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Influenza Vaccines and Antiviral 

Agents 

Description of Technology: The 

subject invention offers candidate DNA 

vaccines to target H5N1, H1N1, H3N2 

and other subtypes of influenza. These 

candidates are designed primarily to 

elicit neutralizing antibodies. The 

candidate vaccines express 

hemagglutinin (H/HA) or neuramidase 

(N/NA) protein that has been codon 

optimized and/or modified at the 

protease cleavage site. The modified 

genes could be used in DNA vaccines, 

in viral vectors, recombinant proteins/ 

particles or combination. The studies 

use proprietary expression systems that 

increase protein expression relative to 

commonly used alternatives. This 

invention potentially provides a vaccine 

strategy for controlling influenza 

epidemics, including avian flu, should 

it cross over to humans; the 1918 strain 

of flu; and seasonal flu strains. In 

addition, this invention is designed to 

lead to a combination vaccine to 

provide a broadly protective vaccine. 

The incorporation of specific cleavage 

site types to facilitate preparation of 

pseudotypes from a variety of strains is 

an important aspect of this invention. 

In addition, HA pseudotyped 

lentiviral vectors are being tested to 

screen for neutralizing abs in patients 

and to screen for diagnostic and 

therapeutic monoclonal abs. 

Applications and Advantages: 

Influenza vaccine for pandemic or 

epidemic application; Potential for 

combination vaccine for broad 

protection, removing need for seasonal 

strain monitoring; DNA vaccines are 

easy to produce and store; No risk of 

reversion to pathogenic strain as with 

live-attenuated virus vaccines. 

Development Status Highlights: Phase 

I clinical trials planned for select 

candidates; DNA vaccine encoding 1918 

influenza virus HA protein protects 

mice against lethal viral challenge; 

Codon optimized for expression in 

human cells. 

Inventors: Gary J. Nabel (VRC/NIAID), 

Wing-pui Kong (VRC/NIAID), Zhi-yong 

Yang (VRC, NIAID), et al. 

Publication: Certain aspects of this 

technology were published in WP Kong 

et al. Protective immunity to lethal 

challenge of the 1918 pandemic 

influenza virus by vaccination. Proc 

Natl Acad Sci USA. 2006 Oct 

24;103(43):15987–15991. Epub 2006 Oct 

16, doi: 10.1073/pnas.0607564103. 

Patent Status: U.S. Provisional 

Application No. 60/774,923 filed 16 Feb 

2006 (HHS Reference No. E–116–2006/ 

0–US–01) and PCT Application No. 

PCT/US2007/004506 filed 16 Feb 2007 

(influenza) (HHS Reference No. E–116–

2006/1–PCT–01); U.S. Patent No. 

7,094,598 issued 22 Aug 2006 (CMV/R) 

(HHS Reference No. E–241–2001/1–US–

01) and associated foreign rights. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Enhanced, Targeted Delivery for DNA 

Vaccines 

Description of Technology: Available 

for licensing from the NIH is a fusion 

protein for enhanced gene delivery. 

Exemplary proteins for achieving this 

improvement comprise an adenovirus 

serotype 5 fiber, penton base and core 

protein V fused to the DNA binding 

domain of HMG. In vitro studies have 

shown the effectiveness of the chimeric 

protein-DNA vaccine co-administration 

by an increase in uptake of ten to twenty 

fold. In particular, the plasmid with the 

chimeric core protein V was delivered 

efficiently to dendritic cells (DC) as well 

as 293T cells. The utilization of this 

chimeric protein could further enhance 

the immune response elicited by DNA 

vaccines. 

Potential Applications: Improved 

DNA vaccine delivery and uptake. 

Inventors: Gary J. Nabel and Wataru 

Akahata (VRC/NIAID). 

Patent Status: U.S. Provisional 

Application No. 60/737,896 filed 18 

Nov 2005 (HHS Reference No. E–043–

2006/0–US–01); U.S. Provisional 

Application No. 60/795,529 filed 26 Apr 

2006 (HHS Reference No. E–043–2006/ 

1–US–01); PCT Application No. PCT/ 

US2006/044525 filed 20 Nov 2006 (HHS 

Reference No. E–043–2006/3–PCT–01) 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Dated: April 30, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8895 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 72, No. 89 / Wednesday, May 9, 2007 / Notices 26407 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: June 13, 2007. 

Time: 1 p.m. to 2:30 p.m. 

Agenda: 1. Approval of Minutes; 2. Report 

from Dr. John E. Niederhuber, NCI Director; 

3. Reports on NCI Budget; DCLG member 

activity; 4. Report on the National 

Community Cancer Center Program, 

Advisory Committee and Pilot Project; 5. 

Public Comment; 6. Action Items and 

Conclusion. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Barbara Guest, Executive 

Secretary, Office of Liaison Activities, 

National Cancer Institute, National Institutes 

of Health, 6116 Executive Blvd, Room 2202, 

Bethesda, MD 20892–8324, 301–496–0307, 

guestb@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Preventive 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: April 30, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2294 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine, Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Clinicl Studies. 

Date: June 4–5, 2007. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Jeanette M. Hosseini, 

Ph.D., Scientific Review Administrator, 

Office of Scientific Review, National Center 

for Complementary and Alternative 

Medicine, NIH, 6707 Democracy Blvd., Suite 

401, Bethesda, MD 20892, (301) 594–9096, 

jeanetteh@mail.nih.gov. 

Dated: May 1, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2292 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine 

Announcement of Stakeholder 

Dialogue 

ACTION: Notice. 

SUMMARY: The National Center for 

Complementary and Alternative 

Medicine (NCCAM) invites the public to 

a Stakeholder Dialogue. Attendees will 

meet the NCCAM Acting Director and 

discuss the Center’s activities and 

priorities. The Dialogue will take place 

on June 20, 2007 in Bethesda, Maryland. 

Representatives from the 

complementary and alternative 

medicine community are particularly 

encouraged to attend. 

Background: The National Center for 

Complementary and Alternative 

Medicine (NCCAM) was established in 

1999 with the mission of exploring 

complementary and alternative healing 

practices in the context of rigorous 

science, training CAM researchers, and 

disseminating authoritative information 

to the public and professionals. 

To date, NCCAM’s efforts to 

rigorously study CAM, to train CAM 

researchers, to conduct outreach, and to 

facilitate integration have been guided 

by NCCAM’s strategic plans located on 

the NCCAM Web site at http:// 

nccam.nih.gov/about/plans/fiveyear/ 

index.htm. 

Request for Participation: The public 

is invited to provide input into the 

NCCAM’s priorities and activities at a 

Stakeholder Dialogue. This event will 

give NCCAM stakeholders an 

opportunity to voice their opinions 

regarding future directions for research, 

training, outreach, and integration in 

complementary and alternative 

medicine (CAM). The Dialogue will be 

held: June 20, 2007, 9 a.m. to 3 p.m., 

Natcher Conference Center, National 

Institutes of Health,Bethesda, Maryland 

20892. 

NCCAM’s acting director will provide 

an overview of NCCAM’s history and 

current activities, followed by a 

discussion with attendees. Dialogue 

attendees are welcome to participate in 

one of three afternoon breakout sessions 

(research, training, and 

communications) wherein there will be 

an opportunity to interact with NCCAM 

senior staff and discuss how NCCAM 

and the CAM community can work 

together in the future. Representatives 

from the complementary and alternative 

medicine community are particularly 

encouraged to attend. Those wishing to 

attend should register by June 15, 2007. 

To register, please visit http:// 

nccam.nih.gov/dialogue. 

For Further Information: To request 

more information, visit the NCCAM 

Web site at http://nccam.nih.gov/ 

dialogue, call 1–888–644–6226, or email info@nccam.gov. 

Dated: May 1, 2007. 

Christy Thomsen, 

Director, Office of Communications and 

Public Liaison, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health. 

[FR Doc. E7–8876 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


sroberts on PROD1PC70 with NOTICES